From allergy to anti-IgE: targeting the cause.
Because of the central role that immunoglobulin (Ig)E has in allergic responses, a mechanism by which allergic diseases might be treated, especially asthma, is to effectively deplete the body of IgE. This paper discusses the basic concepts and the issues behind the biotechnical and clinical development of omalizumab, a recombinant humanized monoclonal antibody to IgE for potential use in the treatment of human allergic disease.
D000888:Antibodies, Anti-Idiotypic / Q000276:immunology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000209:etiology* / Q000276:immunology; D000069444:Omalizumab
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C026408:anti-IgE antibodies; D000069444:Omalizumab